A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Latest Information Update: 27 May 2024
At a glance
- Drugs Olezarsen (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Registrational; Therapeutic Use
- Acronyms BALANCE
- Sponsors Ionis Pharmaceuticals
- 08 Apr 2024 Preliminary results assessing efficacy of olezarsen, presented at the 73rd Annual Scientific Session of the American College of Cardiology.
- 07 Apr 2024 According to an Ionis Pharmaceuticals Media Release, company will host webcast on Monday, April 8 at 10:00 am ET t to discuss the detailed results from the Balance study.
- 07 Apr 2024 According to an Ionis Pharmaceuticals Media Release, based on the results of this study company is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.